Armstrong, April W. http://orcid.org/0000-0003-0064-8707
Park, Sang Hee http://orcid.org/0000-0003-2545-2938
Patel, Vardhaman http://orcid.org/0000-0002-3636-3423
Nicolas, Pierre http://orcid.org/0009-0003-9871-5425
Wang, Wei-Jhih http://orcid.org/0000-0001-7868-5458
Colombo, Matthew J. http://orcid.org/0009-0006-5653-381X
Chirikov, Viktor
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 19 April 2024
Accepted: 31 May 2024
First Online: 22 June 2024
Declarations
:
: April W. Armstrong is a research investigator, scientific advisor, and/or speaker for AbbVie, Almirall, Arcutis, Aslan Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, Leo Pharma, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Sang Hee Park, Vardhaman Patel, Pierre Nicolas, and Matthew J. Colombo are employees and may be shareholders in Bristol Myers Squibb. Wei-Jhih Wang and Viktor Chirikov are employees of OPEN Health Evidence & Access, which has received consulting fees from Bristol Myers Squibb.
: The POETYK PSO-1 trial was conducted in accordance with the requirements of the Declaration of Helsinki of 1964 and its later amendments and the International Council for Harmonisation Good Clinical Practice guideline. The study was reviewed and approved by an independent institutional review board, and all participants provided written informed consent.